In addition, the concomitant administration of [111In]In-DOTAGA-GARP with a 100x excess of unlabelled anti-GARP antibody induces a significant decrease in tumour uptake of [111In]In-DOTAGA-GARP thus demonstrating active targeting of our probe in vivo (Fig. 3E and F). Here, LRRC32 is linked to neoplasm.